DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Women's Health Homepage

New machine learning tool identifies breast lesions likely to become cancerous May help reduce unnecessary surgical procedures

Researchers to assess benefits of 3-D mammo versus 2-D Will follow 165,000 women between ages 45 and 74 through at least 2025

Hypofractionated whole-breast radiotherapy best for early-stage breast cancer patients under 50 Study supports higher dose, shorter form treatment

Study finds mobile mammo patients aren't getting the follow-up imaging they need Socioeconomic factors credited for low adherence rates

Hologic launches SmartCurve breast stabilization system for U.S. consumers A more comfortable mammogram without compromised image quality

Survey finds radiation therapy isn't as scary as it seems Many patients unaware of major technological advances

New MR contrast agent distinguishes aggressive from slow-growing breast cancer Lights up biomarkers in different shades of brightness

Study finds MR detects 98 percent of pregnancy-related breast cancers May also inform surgical management of disease

Hologic introduces its 3Dimensions mammo system to the European market Improvements in accuracy, clarity, workflow and dose

Hologic launches Brevera breast biopsy system in the U.S. Doctors can perform and examine biopsy results in the same room

Molecular breast imaging finds cancers that mammograms don't: study

by Lisa Chamoff , Contributing Reporter
Molecular breast imaging (MBI) detected cancer in several women with dense breasts whose mammograms had been negative, with an incremental cancer detection rate of 7.7 per 1,000 screens, a study has found.

The retrospective study, published in the August issue of the American Journal of Roentgenology, examined data from the supplemental screening program at ProMedica Breast Care in Toledo, Ohio, from 2011 to 2014. After having a mammogram, 1,696 women with dense breast underwent supplementary screening with Gamma Medica’s LumaGEM MBI system, which uses the technetium-99m sestamibi radiopharmaceutical and employs a dual-head digital detector and a special collimator. This resulted in the detection of 13 malignancies, after the mammograms read negative for cancer.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“That’s a significant amount of extra cancers,” Dr. Robin Shermis, medical director at the ProMedica Breast Care Center and one of the study’s authors, told HCB News.

The lesion size ranged from .6 to 2.4 centimeters, with a mean of 1.1 centimeters. About 85 percent of the cancers were node negative, which means the prognosis was better.

“We found them early and they would have otherwise gone undetected by mammography,” Shermis said.

The study also found that the positive predictive value (PPV) for recall was 9.1 percent and the PPV for biopsy was 19.4 percent.

Shermis explained that patients at ProMedica Breast Care with a lifetime risk of at least 20 percent for developing breast cancer receive supplementary screening with MR, while patients with dense breast tissue are recommended to receive supplementary screening with MBI.

“MR is a great test, but it’s very expensive and insurance companies won’t pay for it unless you’re high risk,” Shermis said.

MBI delivers almost instantaneous results, he added.

“This new study in the AJR provides further evidence that women with dense breast tissue have more comfortable and less stressful alternatives to standardized secondary screening studies,” said Philip Croxford, chief executive officer of Gamma Medica, in a statement. “These recent clinical results suggest there is a real alternative to the risk of misdiagnosis and unnecessary biopsies.”

The study by ProMedica follows a study by the Mayo Clinic, published in the AJR last year, which found the addition of MBI to mammography increased the invasive breast cancer detection rate 363 percent, from 1.9 to 8.8 per 1,000 screens.

MBI uses 6 to 8 millicuries, about four times the dose from a digital mammogram, though Shermis said it’s possible to cut the dose in half by scanning for twice as long. While some breast cancer experts don’t recommend MBI for annual screening because of the higher dose, Shermis noted that it was important to weigh the risks with the benefit of detecting cancers earlier.

“Six thousand women, who know the benefits and risks, have yet to say ‘I don’t want it,’” Shermis said.

Women's Health Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED